A Quick Primer On Roche's Immuno-Oncology Assets
Executive Summary
Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.
You may also be interested in...
The IO Switch: Making Tumor-Associated Macrophages Work In Our Favor
Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.
BioNTech, Neon Take A Step Forward In Personalized Cancer Vaccines
Two studies published in Nature July 5 showed that personalized cancer vaccines from BioNTech and Neon Therapeutics delivered potent immune responses in patients with melanoma. Both companies are moving forward with new studies.
NewLink Absorbs Big Blow As Roche Exits IDO Inhibitor Partnership
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.